Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 11;9(21):5638-5640.
doi: 10.1182/bloodadvances.2025017509.

The CAR-HEMATOTOX: ready for prime time

Jan H Frenking  1   2 , Kai Rejeski  3   4
Affiliations
Editorial

The CAR-HEMATOTOX: ready for prime time

Jan H Frenking et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.H.F. has an advisory role with Pfizer; reports honoraria from Bristol Myers Squibb and Stemline; and travel and congress participation grants from Janssen-Cilag. K.R. reports research funding, consultancy fees, honoraria, and travel support from Kite/Gilead; honoraria from Novartis; consultancy fees and honoraria from Bristol Myers Squibb/Celgene; travel support from Pierre Fabre; and consultancy fees from CSL Behring.

Figures

None
From development to clinical application of the CAR-HEMATOTOX score: an overview of its evolution, validation, and future directions. Professional illustration by Somersault18:24.
See this image and copyright information in PMC

Comment on

References

    1. de Boer J, Keijzer K, et al. Keijzer K. Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL. Blood Adv. 2025;9(21):5641–5650. - PubMed
    1. Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865–877. - PubMed
    1. Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499–2513. - PMC - PubMed
    1. Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023;7(21):6589–6598. - PMC - PubMed
    1. Cordas dos Santos D, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667–2678. - PMC - PubMed